Back to Search
Start Over
Insight in miRNome of Long-Term Non-Progressors and Elite Controllers Exposes Potential RNAi Role in Restraining HIV-1 Infection
- Source :
- Repisalud, Instituto de Salud Carlos III (ISCIII), Journal of Clinical Medicine, Journal of Clinical Medicine; Volume 9; Issue 8; Pages: 2452, Journal of Clinical Medicine, Vol 9, Iss 2452, p 2452 (2020)
- Publication Year :
- 2020
- Publisher :
- Multidisciplinary Digital Publishing Institute (MDPI), 2020.
-
Abstract
- Factor de impacto: 4,242 Q1 Long-term non-progressors (LTNP) and elite controllers (EC) represent spontaneous natural models of efficient HIV-1 response in the absence of treatment. The main purposes of this work are to describe the miRNome of HIV-1 infected patients with different extreme phenotypes and identify potentially altered pathways regulated by differentially expressed (DE) miRNAs. The miRNomes from peripheral blood mononuclear cells (PBMCs) of dual phenotype EC-LTNP or LTNP with detectable viremia and HIV-infected patients with typical progression before and after treatment, were obtained through miRNA-Seq and compared among them. The administration of treatment produces 18 DE miRNAs in typical progressors. LTNP condition shows 14 DE miRNA when compared to typical progressors, allowing LTNP phenotype differentiation. A set of four miRNAs: miR-144-3p, miR-18a-5p, miR-451a, and miR-324 is strongly downregulated in LTNP and related to protein regulation as AKT, mTOR, ERK or IKK, involved in immune response pathways. Deregulation of 28 miRNA is observed between EC-LTNP and viremic-LTNP, including previously described anti-HIV miRNAs: miR-29a, associated with LTNP phenotype, and miR-155, targeting different pre-integration complexes such as ADAM10 and TNPO3. A holistic perspective of the changes observed in the miRNome of patients with different phenotypes of HIV-control and non-progression is provided. This study has been conducted within the Spanish AIDS Research Network (RIS), funded by Instituto de Salud Carlos III (Plan Estatal de I+D+I 2013-2016) and co-funded by European Regional Development Fund (ERDF) “A way to build Europe” (RD12/0017/0015 and RD16CIII/0002/0001 projects), and the European Union’s Horizon 2020 Research and Innovation Programme under grant number 681137. The HIV BioBank, integrated in the Spanish AIDS Research Network, is partially funded by the RD16/0025/0019 project as part of the Plan Nacional R + D + I and cofinanced by ISCIII- Subdirección General de Evaluación and el Fondo Europeo de Desarrollo Regional (FEDER). R.A.-S. was supported by the Ministry of Innovation, Science and Universities predoctoral funding (FPU18/05527) and H.E.T.-T. by the ISCIII-PFIS predoctoral program (FI14CIII/00014). Sí
- Subjects :
- ADAM10
miRNA-Seq
lcsh:Medicine
Viremia
HIV-1 infection
Peripheral blood mononuclear cell
ong-term non-progressors
Article
differential expression
elite controllers
03 medical and health sciences
0302 clinical medicine
Immune system
RNA interference
microRNA
biomarker discovery
Medicine
PI3K/AKT/mTOR pathway
030304 developmental biology
0303 health sciences
long-term non-progressors
miRNome
business.industry
lcsh:R
General Medicine
medicine.disease
Phenotype
030220 oncology & carcinogenesis
Immunology
business
Subjects
Details
- Database :
- OpenAIRE
- Journal :
- Repisalud, Instituto de Salud Carlos III (ISCIII), Journal of Clinical Medicine, Journal of Clinical Medicine; Volume 9; Issue 8; Pages: 2452, Journal of Clinical Medicine, Vol 9, Iss 2452, p 2452 (2020)
- Accession number :
- edsair.doi.dedup.....62cb99fc36c5ae1f3b543833593db892